Proteomics International Advances Deals with Singapore and China Partners

Proteomics International Laboratories Ltd (ASX:PIQ) (PILL), the leader in predictive diagnostics for diabetic kidney disease, will advance deals with commercialisation partners in Singapore and China, which is patented in both countries, to the Asian market.

KEY TAKEAWAYS:

• PromarkerD technology has been validated by the peer-reviewed scientific journal EuPA Open Proteomics, the official journal of the European Proteomics Association (EuPA).
• Kidney disease is one of the major complications of diabetes and affects approximately one-third of all adult diabetics. Keeping people alive on dialysis costs more than $100,000 per person per year.
• Globally the diabetes epidemic cost health systems $673 billion dollars in 2015.
• Today there are 231 million people living with diabetes in Asia alone, according to the International Diabetes Federation.
• Worldwide this number is forecast to rise to 642 million people by 2040, and
• 214 million people are predicted to get chronic kidney disease as a result.

Frost & Sullivan states that novel tools like PromarkerD can allow “enhanced management of obesity, diabetes and related complications in the near future”. “If we can stem this health crisis tsunami by identifying and treating people before they are symptomatic we are saving lives, as well as billions of dollars in health costs,” said Dr Lipscombe.

PILL’s diagnostic research is made possible by the company’s proprietary biomarker discovery platform termed Promarker, which searches for protein ‘fingerprints’ in a sample. This disruptive technology can identify proteins that distinguish between people who have a disease and people who do not, using only a simple blood test. It is a powerful alternative to genetic testing.

Request Information